Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide in Overweight or Obesity
NCT07557953Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Cagrilintide with Placebo Cagrilintide (2 arms). Primary endpoint: Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box at Day 127. Started Apr 2026; status: recruiting.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07557953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557953.